Creat membership Creat membership
Sign in

Forgot password?

  • Forgot password?
    Sign Up
  • Confirm
    Sign In
home > search

Now showing items 1 - 16 of 34

  • The impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease

    Solmaz, Dilek   Bakirci, Sibel   Kimyon, Gezmis   Kasapoglu Gunal, Esen   Dogru, Atalay   Bayindir, Ozun   Dalkilic, Ediz   Ozisler, Cem   Can, Meryem   Akar, Servet   Cetin, Gozde Yildirim   Yavuz, Sule   Kilic, Levent   Tarhan, Emine Figen   Kucuksahin, Orhan   Omma, Ahmet   Gonullu, Emel   Yildiz, Fatih   Ersozlu, Emine Duygu   Cinar, Muhammet   Onazi, Atallah   Aydin Tufan, Muge   Erden, Abdulsamet   Yilmaz, Sema   Pehlevan, Seval   Kalyoncu, Umut   Aydin, Sibel Zehra  

    Download Collect
  • Sonographic measurement of Achilles tendon thickness in seronegative spondyloarthropathies

    Aydin, Sibel Zehra   Filippucci, Emilio   Atagündüz, Pamir   Yavuz, Sule   Grassi, Walter   Direskeneli, Haner  

    Download Collect
  • Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

    Elhai, Muriel   Boubaya, Marouane   Distler, Oliver   Smith, Vanessa   Matucci-Cerinic, Marco   Alegre Sancho, Juan José   Truchetet, Marie-Elise   Braun-Moscovici, Yolanda   Iannone, Florenzo   Novikov, Pavel I   Lescoat, Alain   Siegert, Elise   Castellví, Ivan   Airó, Paolo   Vettori, Serena   De Langhe, Ellen   Hachulla, Eric   Erler, Anne   Ananieva, Lidia   Krusche, Martin   López-Longo, F J   Distler, Jörg H W   Hunzelmann, Nicolas   Hoffmann-Vold, Anna-Maria   Riccieri, Valeria   Hsu, Vivien M   Pozzi, Maria R   Ancuta, Codrina   Rosato, Edoardo   Mihai, Carina   Kuwana, Masataka   Saketkoo, Lesley Ann   Chizzolini, Carlo   Hesselstrand, Roger   Ullman, Susanne   Yavuz, Sule   Rednic, Simona   Caimmi, Cristian   Bloch-Queyrat, Coralie   Allanore, Yannick  

    Download Collect
  • Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases.

    Yilmaz, Neslihan   Emmungil, Hakan   Gucenmez, Sercan   Ozen, Gulsen   Yildiz, Fatih   Balkarli, Ayse   Kimyon, Gezmis   Coskun, Belkis Nihan   Dogan, Ismail   Pamuk, Omer Nuri   Yasar, Sule   Cetin, Gozde Yildirim   Yazici, Ayten   Ergulu Esmen, Serpil   Cagatay, Yonca   Yilmaz, Sema   Cefle, Ayse   Sayarlioglu, Mehmet   Kasifoglu, Timucin   Karadag, Omer   Pehlivan, Yavuz   Dalkilic, Ediz   Kisacik, Bunyamin   Cobankara, Veli   Erken, Eren   Direskeneli, Haner   Aksu, Kenan   Yavuz, Sule  

    OBJECTIVE: To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases.; METHODS: Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics.; RESULTS: We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4-48) and bladder cancer was 8 years (6-10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p =3D 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis.; CONCLUSION: Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort.=20
    Download Collect
  • A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression:implications for the pathogenesis

    Vazgiourakis, Vassilios M.   Zervou, Maria I.   Choulaki, Christianna   Bertsias, George   Melissourgaki, Maria   Yilmaz, Neslihan   Sidiropoulos, Prodromos   Plant, Darren   Trouw, Leendert A.   Toes, Rene E.   Kardassis, Dimitris   Yavuz, Sule   Boumpas, Dimitrios T.   Goulielmos, George N.  

    Background In systemic lupus erythematosus (SLE) sustained CD40L expression by T cells and platelets activates a variety of cells via its receptor CD40 contributing to disease pathogenesis. Although CD40 has recently been identified in genome-wide association study as a novel rheumatoid arthritis susceptibility gene such an association has not been documented for SLE. Objective To investigate whether the rs4810485 CD40 single nucleotide polymorphism (SNP) is associated with increased risk for SLE and its impact on CD40 expression. Materials and methods The primary sample set consisted of 351 patients with SLE and 670 matched healthy controls of Greek origin. 158 patients with SLE and 155 controls from Turkey were used as a replication sample. Genotyping of rs4810485 was performed by restriction fragment length polymorphism and the Sequenom MassArray technology. The expression of CD40 mRNA and protein was assessed in unstimulated and lipopolysaccharide-stimulated peripheral blood mononuclear cells by quantitative real time PCR and flow cytometry, respectively. Results The minor allele T of CD40 rs4810485 SNP was significantly under-represented in Greek patients with SLE compared with healthy controls (OR=3D0.65, 95% CI 0.54 to 0.79). The association was replicated in the Turkish cohort (OR=3D0.57, 95% CI 0.41 to 0.80; meta-analysis of 509 patients with SLE and 825 healthy controls: OR=3D0.63, 95% CI 0.53 to 0.74, p =3D 2x10(-8)). In both cases and controls, the rs4810485 G/T and T/T genotypes were associated with significantly reduced CD40 mRNA and protein expression in peripheral blood CD14+ monocytes and CD19+ B cells compared with G/G genotype, both under basal conditions and following stimulation. Conclusions CD40 has been identified as a new susceptibility locus in Greek and Turkish patients with SLE. The rs4810485 minor allele T is under-represented in SLE and correlates with reduced CD40 expression in peripheral blood monocytes and B cells, with potential implications for the regulation of aberrant immune responses in the disease.
    Download Collect
  • Analysis of Systemic Sclerosis-associated Genes in a Turkish Population

    Onat, Ahmet Mesut   Fernandez-Aranguren, Tamara   Serrano-Fernandez, Alberto   Robledo, Gema   Direskeneli, Haner   Sawalha, Amr H.   Yavuz, Sule   Martin, Javier  

    Objective. To evaluate the genetic background of systemic sclerosis ( SSc) in the Turkish population.Methods. There were 354 cases and 718 unaffected controls from Turkey genotyped for the most relevant SSc genetic markers ( IRF5-rs10488631, STAT4-rs3821236, CD247-rs2056626, DNASE1L3-rs35677470, IL12A-rs77583790, and ATG5-rs9373839). Association tests were conducted to identify possible associations.Results. Except for ATG5, all the analyzed genes showed either significant associations ( IRF5: p =3D 1.32E-05, OR 1.76; CD247: p =3D 2.20E-03, OR 0.75) or trends of association ( STAT4: p =3D 0.066, OR 1.21; IL12A: p =3D 0.079, OR 4.07; DNASE1L3: p =3D 0.097, OR 1.41) with the overall disease or with specific phenotypes.Conclusion. The genetic component of SSc seems to be similar between Turks and Europeans.
    Download Collect
  • Comparative characteristics of mu chain and alpha chain transcripts expressed by individual tonsil plasma cells

    Yavuz, Sule   Grammer, Amrie C.   Yavuz, A. Selim   Nanki, Toshihiro   Lipsky, Peter E.  

    Plasma cells (PCs) are one of the two major cell types generated during germinal center reactions. To test the hypothesis that PCs express a unique repertoire of immunoglobulin (Ig) genes resulting from intensive antigenic stimulation and selection, the mutational pattern and distribution of VH gene segments within 178 transcripts amplified from individual IgM and IgA secreting tonsil PCs were analyzed. The results demonstrated that both mu and alpha transcripts expressed repertoires with limited diversity. Moreover, both mu and alpha transcripts were heavily mutated, with a significantly increased mutational frequency noted for alpha compared to mu transcripts (5.0X10-2 vs 1.8X10-2, P<0.001). In addition, both mu and alpha transcripts showed significantly greater targeting of mutations to RGYW motifs (purine/guanine/pyrimidine/A or T) compared to memory B cells. Finally, clonally expanded cells were detected in alpha but not mu PC compartments. These results indicate that antigen driven stimulation and selection shape the entire expressed PC repertoire, but the impact is greater in alpha expressing PCs.
    Download Collect
  • Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life.

    Aydin, Sibel Zehra   Kucuksahin, Orhan   Kilic, Levent   Dogru, Atalay   Bayindir, Ozun   Ozisler, Cem   Omma, Ahmet   Tarhan, Emine Figen   Erden, Abdulsamet   Kimyon, Gezmis   Can, Meryem   Dalkilic, Ediz   Yavuz, Sule   Ureyen, Sibel Bakirci   Gunal, Esen Kasapoglu   Alhussain, Fatima Arslan   Akyol, Lutfi   Balkarli, Ayse   Yilmaz, Sema   Cinar, Muhammet   Aydin, Muge Tufan   Solmaz, Dilek   Mercan, Ridvan   Erten, Sukran   Kalyoncu, Umut  

    Psoriatic arthritis (PsA) may affect different joints, including the spine. The prevalence of spinal involvement is variable depending on the definition and a subset of patients have been identified in cohorts that do not have clinical features of axial disease and yet have imaging findings. Still, there is not a consensus on how and when to screen axial disease. In this study, we aimed to investigate factors associated with being underdiagnosed for axial psoriatic arthritis (axPsA) and its impacts on outcomes. Disease features and outcomes of axPsA according to the physician (n=3D415) were compared with patients with imaging findings only (sacroiliitis fulfilling the modified New York criteria, n=3D112), using data from a real-life PsA registry. Patients with imaging findings only were more frequently women (83/220 (37.7%) vs 29/122 (23.8%); p=3D0.008). This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p<0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p<0.001) than patients who were classified as axPsA. Patient-reported outcomes were similar in both groups. PsA patients, especially women with more severe peripheral disease, have a higher risk of being underdiagnosed for axPsA. The severity of peripheral symptoms may be a risk factor to mask the spinal features of PsA.=20
    Download Collect
  • TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey

    Zervou, Maria I.   Vazgiourakis, Vassilios M.   Yilmaz, Neslihan   Kontaki, Elena   Trouw, Leendert A.   Toes, Rene E.   Bicakcigil, Muge   Boumpas, Dimitrios T.   Yavuz, Sule   Goulielmos, George N.  

    A significant source of variability in the literature on systemic lupus erythematosus (SLE) susceptibility genes has been the inability to replicate genetic findings across different racial or ethnic groups. We investigated whether a single nucleotide polymorphism (SNP) of the STAT4 (rs7574865), PTPN22 (rs2476601), TRAF1/C5 (rs10818488), and C1q (rs292001) genes as well as the 27-bp VNTR polymorphism on intron 4 of eNOS, previously associated with SLE in other populations, are also associated with SLE risk in Turkey. A group of 158 SLE patients and 155 healthy controls were included in this study. A genetic association of the TRAF1/C5, C1q, and eNOS gene polymorphism, but not of STAT4 and PTPN22, was found to confer a degree of risk for SLE. These data highlight the importance of comparative studies in different populations to confirm the previously detected genetic associations. (C) 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
    Download Collect
  • Induced sputum as a method for detection of systemic sclerosis-related interstitial lung disease.

    Yilmaz, Neslihan   Abul, Yasin   Bicakcigil, Muge   Golabi, Pejman   Celikel, Cigdem   Karakurt, Sait   Yavuz, Sule  

    Inducted sputum (IS) is a non-invasive procedure that can be used for collection of airway secretions. The aim of our study is to evaluate the clinical usefulness of IS for detection of airway inflammation in systemic sclerosis (SSc). Bronchoalveolar lavage and IS were performed to 20 patients with SSc. Eighteen patients who were referred to pulmonary medicine for bronchoalveolar lavage due to other reasons were also recruited for cell counts comparisons. Spirometry, echocardiography and thorax CT (HRCT) imaging were also performed to all patients. Mean macrophage and lymphocyte counts were found to be increased in IS of SSc patients compared with that of control (58.4 =C2=B1 14.5% vs. 31.3 =C2=B1 16.3%, 30.2 =C2=B1 15.4% vs. 15.0 =C2=B1 11.5% P < 0.001), whereas mean neutrophil count was lower in the SSc patients (4.1 =C2=B1 4.5% vs. 17.2 =C2=B1 13.1%, P < 0.05). Significant correlations were noted between BAL and IS findings for macrophage (r =3D 0.55, P =3D 0.02) lymphocyte (r =3D 0.65, P < 0.01) and total cell counts (r =3D 0.45, P =3D 0.06). IS is an easy and reliable method for the detection of alveolitis and can be used for early detection of lung involvement in scleroderma.=20
    Download Collect
  • Mapping and predicting mortality from systemic sclerosis

    Elhai, Muriel   Meune, Christophe   Boubaya, Marouane   Avouac, Jerome   Hachulla, Eric   Balbir-Gurman, Alexandra   Riemekasten, Gabriela   Airo, Paolo   Joven, Beatriz   Vettori, Serena   Cozzi, Franco   Ullman, Susanne   Czirjak, Laszlo   Tikly, Mohammed   Mueller-Ladner, U. L. F.   Caramaschi, Paola   Distler, Oliver   Iannone, Florenzo   Ananieva, Lidia P.   Hesselstrand, Roger   Becvar, Radim   Gabrielli, Armando   Damjanov, Nemanja   Salvador, Maria J.   Riccieri, Valeria   Mihai, Carina   Szucs, Gabriella   Walker, Ulrich A.   Hunzelmann, Nicolas   Martinovic, Duska   Smith, Vanessa   Mueller, Carolina de Souza   Montecucco, Carlo Maurizio   Opris, Daniela   Ingegnoli, Francesca   Vlachoyiannopoulos, Panayiotis G.   Stamenkovic, Bojana   Rosato, Edoardo   Heitmann, Stefan   Distler, Joerg H. W.   Zenone, Thierry   Seidel, Matthias   Vacca, Alessandra   De langhe, Ellen   Novak, Srdan   Cutolo, Maurizio   Mouthon, Luc   Henes, Joerg   Chizzolini, Carlo   von Muhlen, Carlos Alberto   Solanki, Kamal   Rednic, Simona   Stamp, Lisa   Anic, Branimir   Santamaria, Vera Ortiz   De Santis, Maria   Yavuz, Sule   Alberto Sifuentes-Giraldo, Walter   Chatelus, Emmanuel   Stork, Jiri   van Laar, Jacob   Loyo, Esthela   de la Pena Lefebvre, Paloma Garcia   Eyerich, Kilian   Cosentino, Vanesa   Jose Alegre-Sancho, Juan   Kowal-Bielecka, Otylia   Rey, Gregoire   Matucci-Cerinic, Marco   Allanore, Yannick  

    Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. Results We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. Conclusion Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients' survival.
    Download Collect
  • Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.

    Yilmaz, Neslihan   Can, Meryem   Kocakaya, Derya   Karakurt, Sait   Yavuz, Sule  

    To assess the effect of mycophenolate mofetil (MMF) on pulmonary functions in patients with systemic sclerosis-associated lung disease (SSc-ILD) who experienced an inadequate response to first line cyclophosphamide (CYC) therapy. Twelve consecutive SSc-ILD patients who received MMF due to inadequate response to CYC as a first line agent, were retrospectively reviewed. Over the course of 2 years, pulmonary function tests (PFT) and high-resolution computed tomography (HRCT) scans were performed. Following initial baseline tests, PFTs were continued at a frequency of every 6 months and HRCT scans were performed every 12 months. After MMF treatment, values of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) improved in three (25%) and two (16.6%) patients, respectively. It is also noted that the evaluation of serial HCRT scans showed no change in 54.5% of patients. Our case series suggested that PFT and imaging scores seemed to be stabilized by MMF in SSc-ILD patients who were inadequate responders to CYC. =C2=A9 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.
    Download Collect
  • IL18 Polymorphism Is Associated with Behcet's Disease But Not Lupus in Patients from Turkey

    Htoon, Jasmine   Nadig, Ajay   Hughes, Travis   Yavuz, Sule   Direskenel, Haner   Saruhan-Direskeneli, Guher   Sawalha, Amr H.  

    Download Collect
  • Rituximab for Remission Induction in a Patient with Relapsing Necrotizing Scleritis Associated with Limited Wegener's Granulomatosis

    Onal, Sumru   Kazokoglu, Haluk   Koc, Aylin   Yavuz, Sule  

    Purpose: The authors report a case of necrotizing scleritis associated with Wegener's granulomatosis (WG), which was treated with rituximab for relapsing disease. Method: Observational case report. Results: A 32-year-old male patient presented with necrotizing scleritis in his left eye. The patient was diagnosed as having limited WG. Cyclophosphamide was begun. Under maintenance treatment with azathioprine two relapses of scleritis occurred. Since a high cumulative dose of cyclophosphamide (22.5 g) was utilized initially, two intravenous infusions of rituximab 1 g was given. Complete resolution of scleritis occurred. Conclusions: Rituximab may be effective to induce remission in patients with scleritis due to WG.
    Download Collect
  • Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis:a European Scleroderma Trials and Research (EUSTAR) analysis

    Becker, Mike   Graf, Nicole   Sauter, Rafael   Allanore, Yannick   Curram, John   Denton, Christopher P.   Khanna, Dinesh   Matucci-Cerinic, Marco   Pena, Janethe de Oliveira   Pope, Janet E.   Matucci-Cerinic, Marco   Guiducci, Serena   Walker, Ulrich   Jaeger, Veronika   Bannert, Bettina   Lapadula, Giovanni   Becvarare, Radim   Cutolo, Maurizio   Valentini, Gabriele   Siegert, Elise   Rednic, Simona   Allanore, Yannick   Montecucco, C.   Carreira, Patricia E.   Novak, Srdan   Czirjak, Laszlo   Varju, Cecilia   Chizzolini, Carlo   Allai, Daniela   Kucharz, Eugene J.   Cozzi, Franco   Rozman, Blaz   Mallia, Carmel   Gabrielli, Armando   Bancel, Dominique Farge   Airo, Paolo   Hesselstrand, Roger   Martinovic, Duska   Balbir-Gurman, Alexandra   Braun-Moscovici, Yolanda   Hunzelmann, Nicolas   Pellerito, Raffaele   Caramaschi, Paola   Black, Carol   Damjanov, Nemanja   Henes, Joerg   Ortiz Santamaria, Vera   Heitmann, Stefan   Seidel, Matthias   Pereira Da Silva, Jose Antonio   Stamenkovic, Bojana   Selmi, Carlo Francesco   Tikly, Mohammed   Denisov, Lev N.   Mueller-Ladner, Ulf   Engelhart, Merete   Hachulla, Eric   Riccieri, Valeria   Ionescu, Ruxandra Maria   Mihai, Carina   Sunderkoetter, Cord   Kuhn, Annegret   Schett, Georg   Distler, Joerg   Meroni, Pierluigi   Ingegnoli, Francesca   Mouthon, Luc   De Keyser, Filip   Smith, Vanessa   Cantatore, Francesco Paolo   Corrado, Ada   Ullman, Susanne   Iversen, Line   Pozzi, Maria Rosa   Eyerich, Kilian   Hein, Ruediger   Knott, Elisabeth   Wiland, Piotr   Szmyrka-Kaczmarek, Magdalena   Sokolik, Renata   Morgiel, Ewa   Madej, Marta   Jose Alegre-Sancho, Juan   Krummel-Lorenz, Brigitte   Saar, Petra   Aringer, Martin   Guenther, Claudia   Anne, Erler   Westhovens, Rene   De langhe, Ellen   Lenaerts, Jan   Anic, Branimir   Baresic, Marko   Mayer, Miroslav   Uprus, Maria   Otsa, Kati   Yavuz, Sule   Radominski, Sebastiao Cezar   Mueller, Carolina de Souza   Azevedo, Valderilio Feijo   Popa, Sergei   Zenone, Thierry   Stebbings, Simon   Highton, John   Mathieu, Alessandro   Vacca, Alessandra   Stamp, Lisa   Chapman, Peter   O'Donnell, John   Solanki, Kamal   Doube, Alan   Veale, Douglas   O'Rourke, Marie   Loyo, Esthela   Li, Mengtao   Rosato, Edoardo   Amoroso, Antonio   Gigante, Antonietta   Oksel, Fahrettin   Yargucu, Figen   Tanaseanu, Cristina-Mihaela   Popescu, Monica   Dumitrascu, Alina   Tiglea, Isabela   Foti, Rosario   Visalli, Elisa   Benenati, Alessia   Amato, Giorgio   Ancuta, Codrina   Chirieac, Rodica   Villiger, Peter   Adler, Sabine   Dan, Diana   de la Pena Lefebvre, Paloma Garcia   Rodriguez Rubio, Silvia   Valero Exposito, Marta   Sibilia, Jean   Chatelus, Emmanuel   Gottenberg, Jacques Eric   Chifflot, Helene   Litinsky, Ira   Del Galdo, Francesco   Venalis, Algirdas   Saketkoo, Lesley Ann   Lasky, Joseph A.   Kerzberg, Eduardo   Montoya, Fabiana   Cosentino, Vanesa   Limonta, Massimiliano   Brucato, Antonio Luca   Lupi, Elide   Spertini, Francois   Ribi, Camillo   Buss, Guillaume   Martin, Thierry   Guffroy, Aurelien   Poindron, Vincent   Chung, Lori   Schmeiser, Tim   Zebryk, Pawel   Riso, Nuno   Riemekasten, Gabriela   Rezus, Elena   Puttini, Piercarlo Sarzi  

    Objectives Mortality and worsening of organ function are desirable endpoints for clinical trials in systemic sclerosis (SSc). The aim of this study was to identify factors that allow enrichment of patients with these endpoints, in a population of patients from the European Scleroderma Trials and Research group database.Methods Inclusion criteria were diagnosis of diffuse SSc and follow-up over 12 +/- 3 months. Disease worsening/organ progression was fulfilled if any of the following events occurred: new renal crisis; decrease of lung or heart function; new echocardiography-suspected pulmonary hypertension or death. In total, 42 clinical parameters were chosen as predictors for the analysis by using (1) imputation of missing data on the basis of multivariate imputation and (2) least absolute shrinkage and selection operator regression.Results Of 1451 patients meeting the inclusion criteria, 706 had complete data on outcome parameters and were included in the analysis. Of the 42 outcome predictors, eight remained in the final regression model. There was substantial evidence for a strong association between disease progression and age, active digital ulcer (DU), lung fibrosis, muscle weakness and elevated C-reactive protein (CRP) level. Active DU, CRP elevation, lung fibrosis and muscle weakness were also associated with a significantly shorter time to disease progression. A bootstrap validation step with 10 000 repetitions successfully validated the model.Conclusions The use of the predictive factors presented here could enable cohort enrichment with patients at risk for overall disease worsening in SSc clinical trials.
    Download Collect
  • Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice:a prospective cohort study

    Elhai, Muriel   Boubaya, Marouane   Distler, Oliver   Smith, Vanessa   Matucci-Cerinic, Marco   Alegre Sancho, Juan Jose   Truchetet, Marie-Elise   Braun-Moscovici, Yolanda   Iannone, Florenzo   Novikov, Pavel I.   Lescoat, Alain   Siegert, Elise   Castellvi, Ivan   Airo, Paolo   Vettori, Serena   De Langhe, Ellen   Hachulla, Eric   Erler, Anne   Ananieva, Lidia   Krusche, Martin   Lopez-Longo, F. J.   Distler, Joerg H. W.   Hunzelmann, Nicolas   Hoffmann-Vold, Anna-Maria   Riccieri, Valeria   Hsu, Vivien M.   Pozzi, Maria R.   Ancuta, Codrina   Rosato, Edoardo   Mihai, Carina   Kuwana, Masataka   Saketkoo, Lesley Ann   Chizzolini, Carlo   Hesselstrand, Roger   Ullman, Susanne   Yavuz, Sule   Rednic, Simona   Caimmi, Cristian   Bloch-Queyrat, Coralie   Allanore, Yannick   Guiducci, Serena   Walker, Ulrich A.   Kyburz, Diego   Lapadula, Giovanni   Maurer, Britta   Jordan, Suzana   Dobrota, Rucsandra   Becvar, Radim   Sierakowsky, Stanislaw   Bielecka, Otylia Kowal   Sulli, Alberto   Cutolo, Maurizio   Cuomo, Giovanna   Nicoara, Ileana   Kahan, Andre   Vlachoyiannopoulos, Panayiotis G.   Montecucco, Carlo Maurizio   Caporali, Roberto   Stork, Jiri   Inanc, Murat   Carreira, Patricia E.   Novak, Srdan   Czirjak, Laszlo   Varju, Cecilia   Kucharz, Eugene J.   Kotulska, Anna   Kopec-Medrek, Magdalena   Widuchowska, Malgorzata   Cozzi, Franco   Rozman, Blaz   Mallia, Carmel   Coleiro, Bernard   Gabrielli, Armando   Farge, Dominique   Wu, Chen   Marjanovic, Zora   Faivre, Helene   Hij, Darin   Dhamadi, Roza   Wollheim, Frank   Scheja, Agneta   Wuttge, Dirk M.   Andreasson, Kristofer   Martinovic, Duska   Balbir-Gurman, Alexandra   Trotta, F.   Lo Monaco, Andrea   Pellerito, Raffaele   Mauriziano, Ospedale   Caramaschi, Paola   Morovic-Vergles, Jadranka   Black, Carol   Denton, Christopher   Damjanov, Nemanja   Henes, Jorg   Santamaria, Vera Ortiz   Heitmann, Stefan   Krasowska, Dorota   Matthias   Hasler, Paul   Burkhardt, Harald   Himsel, Andrea   Bajocchi, Gianluigi   Da Silva, Jose Antonio Pereira   Salvador, Maria Joao   Stamenkovic, Bojana   Stankovic, Aleksandra   Selmi, Carlo Francesco   De Santis, Maria   Tikly, Mohammed   Denisov, Lev N.   Herrick, Ariane   Mueller-Ladner, Ulf   Frerix, Marc   Tarner, Ingo   Scorza, Raffaella   Puppo, Francesco   Engelhart, Merete   Strauss, Gitte   Nielsen, Henrik   Damgaard, Kirsten   Szucs, Gabriela   Mendoza, Antonio Zea   de la Puente, Carlos   Giraldo, Sifuentes W. A.   Midtvedt, Oyvind   Reiseter, Silje   Garen, Torhild   Launay, David   Valesini, Guido   Ionescu, Ruxandra Maria   Groseanu, Laura   Opris, Daniela   Cornateanu, Roxana Sfrent   Ionitescu, Razvan   Gherghe, Ana Maria   Soare, Alina   Gorga, Marilena   Bojinca, Mihai   Milicescu, Mihaela   Sunderkotter, Cord   Kuhn, Annegret   Sandorfi, Nora   Schett, Georg   Beyer, Christian   Meroni, Pierluigi   Ingegnoli, Francesca   Mouthon, Luc   De Keyser, Filip   Melsens, Karin   Cantatore, Francesco P.   Corrado, Ada   Iversen, Line   von Muhlen, Carlos Alberto   Bohn, Jussara Marilu   Lonzetti, Lilian Scussel   Eyerich, Kilian   Hein, Rudiger   Knott, Elisabeth   Wiland, Piotr   Szmyrka-Kaczmarek, Magdalena   Sokolik, Renata   Morgiel, Ewa   Madej, Marta   Houssiau, Frederic A.   Krummel-Lorenz, Brigitte   Saar, Petra   Aringer, Martin   Gunther, Claudia   Westhovens, Rene   Lenaerts, Jan   Anic, Branimir   Baresic, Marko   Mayer, Miroslav   Uprus, Maria   Otsa, Kati   Granel, Brigitte   Muller, Carolina de Souza   Radominski, Sebastiao C.   Azevedo, Valderilio F.   Jimenez, Sergio   Busquets, Joanna   Agachi, Svetlana   Groppa, Liliana   Chiaburu, Lealea   Russu, Eugen   Popa, Sergei   Zenone, Thierry   Pileckyte, Margarita   Mathieu, Alessandro   Vacca, Alessandra   Sampaio-Barros, Percival D.   Yoshinari, Natalino H.   Marangoni, Roberta G.   Martin, Patricia   Fuocco, Luiza   Stebbings, Simon   Highton, John   Chapman, Peter   O'Donnell, John   Stamp, Lisa   Doube, Alan   Solanki, Kamal   Veale, Douglas   O'Rourke, Marie   Loyo, Esthela   Li, Mengtao   Mohamed, Walid Ahmed Abdel Atty   Amoroso, Antonio   Gigante, Antonietta   Oksel, Fahrettin   Yargucu, Figen   Tanaseanu, Cristina-Mihaela   Popescu, Monica   Dumitrascu, Alina   Tiglea, Isabela   Foti, Rosario   Chirieac, Rodica   Furst, Daniel   Villiger, Peter   Adler, Sabine   van Laar, Jacob   Kayser, Cristiane   Fathi, Nihal   Hassanien, Manal   Lefebvre, Paloma Garcia de la Pena   Rubio, Silvia Rodriguez   Exposito, Marta Valero   Chatelus, Emmanuel   Sibilia, Jean   Gottenberg, Jacques Eric   Chifflot, Helene   Litinsky, Ira   Emery, Paul   Buch, Maya   Del Galdo, Francesco   Venalis, Algirdas   Butrimiene, Irena   Venalis, Paulius   Rugiene, Rita   Karpec, Diana   Lasky, Joseph A.   Cosentino, Vanesa   Kerzberg, Eduardo   Montoya, Fabiana   Bianchi, Washington   Carneiro, Sueli   Maretti, Giselle Baptista   Bianchi, Dante Valdetaro   Limonta, Massimiliano   Brucato, Antonio Luca   Lupi, Elide   Rosner, Itzhak   Rozenbaum, Michael   Slobodin, Gleb   Boulman, Nina   Rimar, Doron   Couto, Maura   Kahl, Sarah   Chen, Fei   McCloskey, Deborah   Malveaux, Halina   Spertini, Francois   Ribi, Camillo   Buss, Guillaume   Martin, Thierry   Guffroy, Aurelien   Poindron, Vincent   Chotchaeva, Fatima   Mukhin, Nikolay A.   Moiseev, Sergey  

    Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice. Methods We performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were adverse events, skin fibrosis improvement, lung fibrosis worsening and steroids use among propensity score-matched patients treated or not with rituximab. Results 254 patients were treated with rituximab, in 58% for lung and in 32% for skin involvement. After a median follow-up of 2 years, about 70% of the patients had no side effect. Comparison of treated patients with 9575 propensity-score matched patients showed that patients treated with rituximab were more likely to have skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; OR: 2.79 [1.47-5.32]; p=3D0.002). Treated patients did not have significantly different rates of decrease in forced vital capacity (FVC)>10% (OR: 1.03 [0.55-1.94]; p=3D0.93) nor in carbon monoxide diffusing capacity (DLCO) decrease. Patients having received rituximab were more prone to stop or decrease steroids (OR: 2.34 [1.56-3.53], p<0.0001). Patients treated concomitantly with mycophenolate mofetil had a trend for better outcomes as compared with patients receiving rituximab alone (delta FVC: 5.22 [0.83-9.62]; p=3D0.019 as compared with controls vs 3 [0.66-5.35]; p=3D0.012). Conclusion Rituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.
    Download Collect
1 2 3


If you have any feedback, Please follow the official account to submit feedback.

Turn on your phone and scan

Submit Feedback